This article was originally published by IBD News Today on 20 October 2017 and can be accessed here.
Celgene has recently presented positive data from two of its phase 2 studies: the STEPSTONE and TOUCHSTONE studies, which looked at the company’s investigational compound ozanimod (RPC-1063) as a therapy for Crohn’s disease and ulcerative colitis:
“The ongoing, open-label STEPSTONE study (NCT02531113) enrolled patients with moderately to severely active Crohn’s disease and has two periods — induction and extension. Patients are first enrolled in an induction period of 12 weeks, where they all receive 1.0 mg of ozanimod daily. Patients who complete the induction period may then be eligible to enter the 100-week extension period where they will continue to receive study medication.
Celgene presented the data for the induction period that included 69 patients (with a mean age of 37.7 years) with moderately to severely active Crohn’s disease.
Following the 12-week treatment period, researchers detected that the simple endoscopic score for Crohn’s disease (SES-CD) was reduced by more than 50% and 25% in 27% and 43% of patients, respectively.”
Read the full story here.